Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Horisaki

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
The Journal of Dermatology|September 13, 2024
Comparison of efficacy between anti-PD-1 antibody monotherapy and nivolumab plus ipilimumab therapy as first-line immunotherapy for advanced mucosal melanoma in Japanese patients: A single-center, retrospective cohort studyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology|February 7, 2025
Prognostic value of the CONUT score with immune checkpoint inhibitors as first-line therapy for metastatic malignant melanomaKen Horisaki, Shusuke Yoshikawa, Shoichiro Mori, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
The Journal of Dermatology|September 13, 2024
Comparison of efficacy between anti-PD-1 antibody monotherapy and nivolumab plus ipilimumab therapy as first-line immunotherapy for advanced mucosal melanoma in Japanese patients: A single-center, retrospective cohort studyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology|February 7, 2025
Prognostic value of the CONUT score with immune checkpoint inhibitors as first-line therapy for metastatic malignant melanomaKen Horisaki, Shusuke Yoshikawa, Shoichiro Mori, et al.
Pageof 2